{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T20:17:19Z","timestamp":1793823439960,"version":"4.6.1"},"reference-count":103,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T00:00:00Z","timestamp":1772841600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T00:00:00Z","timestamp":1772841600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1038\/s41409-026-02817-0","type":"journal-article","created":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T06:47:31Z","timestamp":1772866051000},"page":"373-384","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Chronic graft-versus-host disease: Current situation and unmet needs \u2014 A European position statement"],"prefix":"10.1038","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3474-0002","authenticated-orcid":false,"given":"Florent","family":"Malard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zinaida","family":"Peric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7261-2765","authenticated-orcid":false,"given":"Annalisa","family":"Ruggeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Gedde-Dahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7171-4997","authenticated-orcid":false,"given":"Ali","family":"Bazarbachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Ciceri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varun","family":"Mehra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Blaise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6022-2567","authenticated-orcid":false,"given":"Francesca","family":"Kinsella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7568-8239","authenticated-orcid":false,"given":"Helene","family":"Schoemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"Sanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1544-9911","authenticated-orcid":false,"given":"Francesca","family":"Bonifazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7470-2994","authenticated-orcid":false,"given":"Moniek","family":"de Witte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linde","family":"Morsink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5240-9815","authenticated-orcid":false,"given":"Raphael","family":"Duarte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3097-2532","authenticated-orcid":false,"given":"Alexandros","family":"Spyridonidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Tavori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hildegard T.","family":"Greinix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnon","family":"Nagler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2295-2187","authenticated-orcid":false,"given":"Ernst","family":"Holler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6565-3393","authenticated-orcid":false,"given":"Robert","family":"Zeiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7264-808X","authenticated-orcid":false,"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,7]]},"reference":[{"key":"2817_CR1","doi-asserted-by":"publisher","first-page":"6283","DOI":"10.1182\/bloodadvances.2020003418","volume":"4","author":"O Penack","year":"2020","unstructured":"Penack O, Peczynski C, Mohty M, Yakoub-Agha I, Styczynski J, Montoto S, et al. How much has allogeneic stem cell transplant\u2013related mortality improved since the 1980s? A retrospective analysis from the EBMT. Blood Adv. 2020;4:6283\u201390. https:\/\/doi.org\/10.1182\/bloodadvances.2020003418.","journal-title":"Blood Adv"},{"key":"2817_CR2","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMoa1004383","volume":"363","author":"TA Gooley","year":"2010","unstructured":"Gooley TA, Chien JW, Pergam SA, Hingorani S, Sorror ML, Boeckh M, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med. 2010;363:2091\u2013101. https:\/\/doi.org\/10.1056\/NEJMoa1004383.","journal-title":"N Engl J Med"},{"key":"2817_CR3","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.bbmt.2014.04.021","volume":"20","author":"F Malard","year":"2014","unstructured":"Malard F, Chevallier P, Guillaume T, Delaunay J, Rialland F, Harousseau JL, et al. Continuous reduced nonrelapse mortality after allogeneic hematopoietic stem cell transplantation: a single-institution\u2019s three decade experience. Biol Blood Marrow Transpl. 2014;20:1217\u201323. https:\/\/doi.org\/10.1016\/j.bbmt.2014.04.021.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2817_CR4","doi-asserted-by":"publisher","first-page":"4278","DOI":"10.1182\/bloodadvances.2021004941","volume":"5","author":"Z DeFilipp","year":"2021","unstructured":"DeFilipp Z, Alousi AM, Pidala JA, Carpenter PA, Onstad LE, Arai S, et al. Nonrelapse mortality among patients diagnosed with chronic GVHD: an updated analysis from the Chronic GVHD Consortium. Blood Adv. 2021;5:4278\u201384. https:\/\/doi.org\/10.1182\/bloodadvances.2021004941.","journal-title":"Blood Adv"},{"key":"2817_CR5","doi-asserted-by":"publisher","first-page":"74","DOI":"10.46989\/001c.124926","volume":"6","author":"R Shah","year":"2024","unstructured":"Shah R, Murphy D, Logue M, Jerkins J, Jallouk A, Adetola K, et al. Multidisciplinary Management of Morbidities Associated with Chronic Graft-Versus-Host Disease. Clin Hematol Int. 2024;6:74\u201388. https:\/\/doi.org\/10.46989\/001c.124926.","journal-title":"Clin Hematol Int"},{"key":"2817_CR6","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.3324\/haematol.2018.192930","volume":"103","author":"JL Stephanie","year":"2018","unstructured":"Stephanie JL, Lynn O, Eric JC, Bronwen ES, Heather SLJ, Karen LS, et al. Patient-reported outcomes and health status associated with chronic graft-versus-host disease. Haematologica. 2018;103:1535\u201341. https:\/\/doi.org\/10.3324\/haematol.2018.192930.","journal-title":"Haematologica"},{"key":"2817_CR7","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.bbmt.2016.09.023","volume":"23","author":"KR Cooke","year":"2017","unstructured":"Cooke KR, Luznik L, Sarantopoulos S, Hakim FT, Jagasia M, Fowler DH, et al. The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease. Biol Blood Marrow Transpl. 2017;23:211\u201334. https:\/\/doi.org\/10.1016\/j.bbmt.2016.09.023.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2817_CR8","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1146\/annurev-immunol-102119-073227","volume":"39","author":"GR Hill","year":"2021","unstructured":"Hill GR, Betts BC, Tkachev V, Kean LS, Blazar BR. Current Concepts and Advances in Graft-Versus-Host Disease Immunology. Annu Rev Immunol. 2021;39:19\u201349. https:\/\/doi.org\/10.1146\/annurev-immunol-102119-073227.","journal-title":"Annu Rev Immunol"},{"key":"2817_CR9","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","volume":"21","author":"MH Jagasia","year":"2015","unstructured":"Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transpl. 2015;21:389\u2013401.e381. https:\/\/doi.org\/10.1016\/j.bbmt.2014.12.001.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2817_CR10","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.jtct.2021.05.004","volume":"27","author":"Z DeFilipp","year":"2021","unstructured":"DeFilipp Z, Couriel DR, Lazaryan A, Bhatt VR, Buxbaum NP, Alousi AM, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2020 Treatment of Chronic GVHD Report. Transpl Cell Ther. 2021;27:729\u201337. https:\/\/doi.org\/10.1016\/j.jtct.2021.05.004.","journal-title":"Transpl Cell Ther"},{"key":"2817_CR11","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1016\/s2352-3026(23)00342-3","volume":"11","author":"O Penack","year":"2024","unstructured":"Penack O, Marchetti M, Aljurf M, Arat M, Bonifazi F, Duarte RF, et al. Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. Lancet Haematol. 2024;11:e147\u2013e159. https:\/\/doi.org\/10.1016\/s2352-3026(23)00342-3.","journal-title":"Lancet Haematol"},{"key":"2817_CR12","doi-asserted-by":"publisher","first-page":"2964","DOI":"10.1182\/blood.V80.12.2964.2964","volume":"80","author":"JH Antin","year":"1992","unstructured":"Antin JH, Ferrara JL. Cytokine dysregulation and acute graft-versus-host disease. Blood. 1992;80:2964\u20138.","journal-title":"Blood"},{"key":"2817_CR13","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1182\/blood.V75.4.1011.1011","volume":"75","author":"E Holler","year":"1990","unstructured":"Holler E, Kolb HJ, M\u00f6ller A, Kempeni J, Liesenfeld S, Pechumer H, et al. Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation. Blood. 1990;75:1011\u20136.","journal-title":"Blood"},{"key":"2817_CR14","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41572-023-00438-1","volume":"9","author":"F Malard","year":"2023","unstructured":"Malard F, Holler E, Sandmaier BM, Huang H, Mohty M. Acute graft-versus-host disease. Nat Rev Dis Prim. 2023;9:27 https:\/\/doi.org\/10.1038\/s41572-023-00438-1.","journal-title":"Nat Rev Dis Prim"},{"key":"2817_CR15","doi-asserted-by":"publisher","first-page":"3804","DOI":"10.1182\/blood-2007-05-091074","volume":"110","author":"X Chen","year":"2007","unstructured":"Chen X, Vodanovic-Jankovic S, Johnson B, Keller M, Komorowski R, Drobyski WR. Absence of regulatory T-cell control of TH1 and TH17 cells is responsible for the autoimmune-mediated pathology in chronic graft-versus-host disease. Blood. 2007;110:3804\u201313. https:\/\/doi.org\/10.1182\/blood-2007-05-091074.","journal-title":"Blood"},{"key":"2817_CR16","doi-asserted-by":"publisher","unstructured":"Forcade E, Paz K, Flynn R, Griesenauer B, Amet T, Li W et al. An activated Th17-prone T cell subset involved in chronic graft-versus-host disease sensitive to pharmacological inhibition. JCI Insight 2017;2; https:\/\/doi.org\/10.1172\/jci.insight.92111.","DOI":"10.1172\/jci.insight.92111"},{"key":"2817_CR17","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/bmt.2013.215","volume":"49","author":"F Malard","year":"2014","unstructured":"Malard F, Bossard C, Brissot E, Chevallier P, Guillaume T, Delaunay J, et al. Increased Th17\/Treg ratio in chronic liver GVHD. Bone Marrow Transpl. 2014;49:539\u201344. https:\/\/doi.org\/10.1038\/bmt.2013.215.","journal-title":"Bone Marrow Transpl"},{"key":"2817_CR18","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1056\/NEJMra1703472","volume":"377","author":"R Zeiser","year":"2017","unstructured":"Zeiser R, Blazar BR. Pathophysiology of Chronic Graft-versus-Host Disease and Therapeutic Targets. N Engl J Med. 2017;377:2565\u201379. https:\/\/doi.org\/10.1056\/NEJMra1703472.","journal-title":"N Engl J Med"},{"key":"2817_CR19","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.bbmt.2007.10.009","volume":"14","author":"HT Greinix","year":"2008","unstructured":"Greinix HT, Pohlreich D, Kouba M, K\u00f6rm\u00f6czi U, Lohmann I, Feldmann K, et al. Elevated numbers of immature\/transitional CD21- B lymphocytes and deficiency of memory CD27+ B cells identify patients with active chronic graft-versus-host disease. Biol Blood Marrow Transpl. 2008;14:208\u201319. https:\/\/doi.org\/10.1016\/j.bbmt.2007.10.009.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2817_CR20","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.1182\/blood.2020008040","volume":"137","author":"W Jia","year":"2021","unstructured":"Jia W, Poe JC, Su H, Anand S, Matsushima GK, Rathmell JC, et al. BAFF promotes heightened BCR responsiveness and manifestations of chronic GVHD after allogeneic stem cell transplantation. Blood. 2021;137:2544\u201357. https:\/\/doi.org\/10.1182\/blood.2020008040.","journal-title":"Blood"},{"key":"2817_CR21","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1182\/blood-2014-04-571125","volume":"124","author":"A Khoder","year":"2014","unstructured":"Khoder A, Sarvaria A, Alsuliman A, Chew C, Sekine T, Cooper N, et al. Regulatory B cells are enriched within the IgM memory and transitional subsets in healthy donors but are deficient in chronic GVHD. Blood. 2014;124:2034\u201345. https:\/\/doi.org\/10.1182\/blood-2014-04-571125.","journal-title":"Blood"},{"key":"2817_CR22","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1182\/blood-2017-05-782466","volume":"130","author":"JC Poe","year":"2017","unstructured":"Poe JC, Jia W, Su H, Anand S, Rose JJ, Tata PV, et al. An aberrant NOTCH2-BCR signaling axis in B cells from patients with chronic GVHD. Blood. 2017;130:2131\u201345. https:\/\/doi.org\/10.1182\/blood-2017-05-782466.","journal-title":"Blood"},{"key":"2817_CR23","doi-asserted-by":"publisher","first-page":"3865","DOI":"10.1182\/blood-2008-09-177840","volume":"113","author":"S Sarantopoulos","year":"2009","unstructured":"Sarantopoulos S, Stevenson KE, Kim HT, Cutler CS, Bhuiya NS, Schowalter M, et al. Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease. Blood. 2009;113:3865\u201374. https:\/\/doi.org\/10.1182\/blood-2008-09-177840.","journal-title":"Blood"},{"key":"2817_CR24","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1182\/blood.2021011867","volume":"138","author":"R Chakraverty","year":"2021","unstructured":"Chakraverty R, Teshima T. Graft-versus-host disease: a disorder of tissue regeneration and repair. Blood. 2021;138:1657\u201365. https:\/\/doi.org\/10.1182\/blood.2021011867.","journal-title":"Blood"},{"key":"2817_CR25","doi-asserted-by":"publisher","first-page":"4266","DOI":"10.1172\/jci75935","volume":"124","author":"KA Alexander","year":"2014","unstructured":"Alexander KA, Flynn R, Lineburg KE, Kuns RD, Teal BE, Olver SD, et al. CSF-1-dependant donor-derived macrophages mediate chronic graft-versus-host disease. J Clin Investig. 2014;124:4266\u201380. https:\/\/doi.org\/10.1172\/jci75935.","journal-title":"J Clin Investig"},{"key":"2817_CR26","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1136\/annrheumdis-2016-210294","volume":"76","author":"CW Chen","year":"2017","unstructured":"Chen CW, Beyer C, Liu J, Maier C, Li C, Trinh-Minh T, et al. Pharmacological inhibition of porcupine induces regression of experimental skin fibrosis by targeting Wnt signalling. Ann Rheum Dis. 2017;76:773\u20138. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210294.","journal-title":"Ann Rheum Dis"},{"key":"2817_CR27","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.bbmt.2020.01.014","volume":"26","author":"E Marinelli Busilacchi","year":"2020","unstructured":"Marinelli Busilacchi E, Costantini A, Mancini G, Tossetta G, Olivieri J, Poloni A, et al. Nilotinib Treatment of Patients Affected by Chronic Graft-versus-Host Disease Reduces Collagen Production and Skin Fibrosis by Downmodulating the TGF-\u03b2 and p-SMAD Pathway. Biol Blood Marrow Transpl. 2020;26:823\u201334. https:\/\/doi.org\/10.1016\/j.bbmt.2020.01.014.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2817_CR28","doi-asserted-by":"publisher","first-page":"5693","DOI":"10.4049\/jimmunol.163.10.5693","volume":"163","author":"LL McCormick","year":"1999","unstructured":"McCormick LL, Zhang Y, Tootell E, Gilliam AC. Anti-TGF-beta treatment prevents skin and lung fibrosis in murine sclerodermatous graft-versus-host disease: a model for human scleroderma. J Immunol. 1999;163:5693\u20139.","journal-title":"J Immunol"},{"key":"2817_CR29","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1182\/blood-2007-01-071043","volume":"110","author":"S Svegliati","year":"2007","unstructured":"Svegliati S, Olivieri A, Campelli N, Luchetti M, Poloni A, Trappolini S, et al. Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease. Blood. 2007;110:237\u201341. https:\/\/doi.org\/10.1182\/blood-2007-01-071043.","journal-title":"Blood"},{"key":"2817_CR30","doi-asserted-by":"publisher","first-page":"3088","DOI":"10.4049\/jimmunol.168.6.3088","volume":"168","author":"Y Zhang","year":"2002","unstructured":"Zhang Y, McCormick LL, Desai SR, Wu C, Gilliam AC. Murine sclerodermatous graft-versus-host disease, a model for human scleroderma: cutaneous cytokines, chemokines, and immune cell activation. J Immunol. 2002;168:3088\u201398. https:\/\/doi.org\/10.4049\/jimmunol.168.6.3088.","journal-title":"J Immunol"},{"key":"2817_CR31","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1016\/s0140-6736(02)08907-9","volume":"359","author":"BC Biedermann","year":"2002","unstructured":"Biedermann BC, Sahner S, Gregor M, Tsakiris DA, Jeanneret C, Pober JS, et al. Endothelial injury mediated by cytotoxic T lymphocytes and loss of microvessels in chronic graft versus host disease. Lancet. 2002;359:2078\u201383. https:\/\/doi.org\/10.1016\/s0140-6736(02)08907-9.","journal-title":"Lancet"},{"key":"2817_CR32","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1182\/blood.2019003369","volume":"136","author":"KA Markey","year":"2020","unstructured":"Markey KA, Schluter J, Gomes ALC, Littmann ER, Pickard AJ, Taylor BP, et al. The microbe-derived short-chain fatty acids butyrate and propionate are associated with protection from chronic GVHD. Blood. 2020;136:130\u20136. https:\/\/doi.org\/10.1182\/blood.2019003369.","journal-title":"Blood"},{"key":"2817_CR33","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1038\/s41423-023-01054-5","volume":"20","author":"D Yang","year":"2023","unstructured":"Yang D, Almanzar N, Chiu IM. The role of cellular and molecular neuroimmune crosstalk in gut immunity. Cell Mol Immunol. 2023;20:1259\u201369. https:\/\/doi.org\/10.1038\/s41423-023-01054-5.","journal-title":"Cell Mol Immunol"},{"key":"2817_CR34","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1172\/jci82587","volume":"126","author":"HD Nguyen","year":"2016","unstructured":"Nguyen HD, Chatterjee S, Haarberg KM, Wu Y, Bastian D, Heinrichs J, et al. Metabolic reprogramming of alloantigen-activated T cells after hematopoietic cell transplantation. J Clin Investig. 2016;126:1337\u201352. https:\/\/doi.org\/10.1172\/jci82587.","journal-title":"J Clin Investig"},{"key":"2817_CR35","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1016\/j.bbmt.2020.06.014","volume":"26","author":"D Lynch Kelly","year":"2020","unstructured":"Lynch Kelly D, Farhadfar N, Starkweather A, Garrett TJ, Yao Y, Wingard JR, et al. Global Metabolomics in Allogeneic Hematopoietic Cell Transplantation Recipients Discordant for Chronic Graft-versus-Host Disease. Biol Blood Marrow Transpl. 2020;26:1803\u201310. https:\/\/doi.org\/10.1016\/j.bbmt.2020.06.014.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2817_CR36","doi-asserted-by":"publisher","unstructured":"Malard F, Dore J, Gaugler B, Mohty M Introduction to host microbiome symbiosis in health and disease. Mucosal Immunol 2020: 1-8. e-pub ahead of print 2020\/12\/11. https:\/\/doi.org\/10.1038\/s41385-020-00365-4.","DOI":"10.1038\/s41385-020-00365-4"},{"key":"2817_CR37","doi-asserted-by":"publisher","unstructured":"Poe JC, Fang J, Zhang D, Lee MR, DiCioccio RA, Su H et al. Single-cell landscape analysis unravels molecular programming of the human B cell compartment in chronic GVHD. JCI insight 2023; 8. https:\/\/doi.org\/10.1172\/jci.insight.169732","DOI":"10.1172\/jci.insight.169732"},{"key":"2817_CR38","doi-asserted-by":"publisher","first-page":"100246","DOI":"10.1016\/j.xjidi.2023.100246","volume":"4","author":"RK Rosenstein","year":"2024","unstructured":"Rosenstein RK, Rose JJ, Brooks SR, Tsai WL, Gadina M, Pavletic SZ, et al. Identification of Fibroinflammatory and Fibrotic Transcriptomic Subsets of Human Cutaneous Sclerotic Chronic Graft-Versus-Host Disease. JID Innov. 2024;4:100246. https:\/\/doi.org\/10.1016\/j.xjidi.2023.100246.","journal-title":"JID Innov"},{"key":"2817_CR39","doi-asserted-by":"publisher","first-page":"3036","DOI":"10.1182\/bloodadvances.2021005103","volume":"6","author":"Y Wu","year":"2022","unstructured":"Wu Y, Mealer C, Schutt S, Wilson CL, Bastian D, Sofi MH, et al. MicroRNA-31 regulates T-cell metabolism via HIF1\u03b1 and promotes chronic GVHD pathogenesis in mice. Blood Adv. 2022;6:3036\u201352. https:\/\/doi.org\/10.1182\/bloodadvances.2021005103.","journal-title":"Blood Adv"},{"key":"2817_CR40","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1182\/bloodadvances.2021004707","volume":"6","author":"H Zouali","year":"2022","unstructured":"Zouali H, Lemasson J, Calugareanu A, Battail C, Michonneau D, le Buanec H, et al. RNA sequencing of chronic GVHD skin lesions defines shared and unique inflammatory pathways characterizing lichen planus and morphea. Blood Adv. 2022;6:2805\u201311. https:\/\/doi.org\/10.1182\/bloodadvances.2021004707.","journal-title":"Blood Adv"},{"key":"2817_CR41","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1038\/s41409-025-02697-w","volume":"60","author":"D Pulanic","year":"2025","unstructured":"Pulanic D, Peczynski C, Boreland W, Rautenberg C, Kr\u00f6ger N, Michonneau D, et al. Chronic Graft-versus-Host disease trends over 30 years - a study by the EBMT transplant complications working party. Bone Marrow Transpl. 2025;60:1436\u201344. https:\/\/doi.org\/10.1038\/s41409-025-02697-w.","journal-title":"Bone Marrow Transpl"},{"key":"2817_CR42","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1182\/blood.v100.2.406","volume":"100","author":"SJ Lee","year":"2002","unstructured":"Lee SJ, Klein JP, Barrett AJ, Ringden O, Antin JH, Cahn JY, et al. Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood. 2002;100:406\u201314. https:\/\/doi.org\/10.1182\/blood.v100.2.406.","journal-title":"Blood"},{"key":"2817_CR43","doi-asserted-by":"publisher","first-page":"3685","DOI":"10.1200\/jco.2001.19.16.3685","volume":"19","author":"C Cutler","year":"2001","unstructured":"Cutler C, Giri S, Jeyapalan S, Paniagua D, Viswanathan A, Antin JH. Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis. J Clin Oncol. 2001;19:3685\u201391. https:\/\/doi.org\/10.1200\/jco.2001.19.16.3685.","journal-title":"J Clin Oncol"},{"key":"2817_CR44","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1056\/NEJMoa1203517","volume":"367","author":"C Anasetti","year":"2012","unstructured":"Anasetti C, Logan BR, Lee SJ, Waller EK, Weisdorf DJ, Wingard JR, et al. Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med. 2012;367:1487\u201396. https:\/\/doi.org\/10.1056\/NEJMoa1203517.","journal-title":"N Engl J Med"},{"key":"2817_CR45","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/nrclinonc.2015.128","volume":"13","author":"CG Kanakry","year":"2016","unstructured":"Kanakry CG, Fuchs EJ, Luznik L. Modern approaches to HLA-haploidentical blood or marrow transplantation. Nat Rev Clin Oncol. 2016;13:10\u201324. https:\/\/doi.org\/10.1038\/nrclinonc.2015.128.","journal-title":"Nat Rev Clin Oncol"},{"key":"2817_CR46","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","volume":"388","author":"J Bola\u00f1os-Meade","year":"2023","unstructured":"Bola\u00f1os-Meade J, Hamadani M, Wu J, Al Malki MM, Martens MJ, Runaas L, et al. Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis. N Engl J Med. 2023;388:2338\u201348. https:\/\/doi.org\/10.1056\/NEJMoa2215943.","journal-title":"N Engl J Med"},{"key":"2817_CR47","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1056\/NEJMoa2503189","volume":"393","author":"DJ Curtis","year":"2025","unstructured":"Curtis DJ, Patil SS, Reynolds J, Purtill D, Lewis C, Ritchie DS, et al. Graft-versus-Host Disease Prophylaxis with Cyclophosphamide and Cyclosporin. N Engl J Med. 2025;393:243\u201354. https:\/\/doi.org\/10.1056\/NEJMoa2503189.","journal-title":"N Engl J Med"},{"key":"2817_CR48","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/j.bbmt.2015.02.014","volume":"21","author":"F Malard","year":"2015","unstructured":"Malard F, Milpied N, Blaise D, Chevallier P, Michallet M, Lioure B, et al. Effect of graft source on unrelated donor hemopoietic stem cell transplantation in adults with acute myeloid leukemia after reduced-intensity or nonmyeloablative conditioning: a study from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. Biol Blood Marrow Transpl. 2015;21:1059\u201367. https:\/\/doi.org\/10.1016\/j.bbmt.2015.02.014.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2817_CR49","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1056\/nejm200006223422501","volume":"342","author":"V Rocha","year":"2000","unstructured":"Rocha V, Wagner JE Jr, Sobocinski KA, Klein JP, Zhang MJ, Horowitz MM, et al. Graft-versus-host disease in children who have received a cord-blood or bone marrow transplant from an HLA-identical sibling. Eurocord and International Bone Marrow Transplant Registry Working Committee on Alternative Donor and Stem Cell Sources. N Engl J Med. 2000;342:1846\u201354. https:\/\/doi.org\/10.1056\/nejm200006223422501.","journal-title":"N Engl J Med"},{"key":"2817_CR50","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1056\/NEJMoa041276","volume":"351","author":"MJ Laughlin","year":"2004","unstructured":"Laughlin MJ, Eapen M, Rubinstein P, Wagner JE, Zhang MJ, Champlin RE, et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med. 2004;351:2265\u201375. https:\/\/doi.org\/10.1056\/NEJMoa041276.","journal-title":"N Engl J Med"},{"key":"2817_CR51","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1182\/blood-2014-01-514752","volume":"124","author":"G Soci\u00e9","year":"2014","unstructured":"Soci\u00e9 G, Ritz J. Current issues in chronic graft-versus-host disease. Blood. 2014;124:374\u201384. https:\/\/doi.org\/10.1182\/blood-2014-01-514752.","journal-title":"Blood"},{"key":"2817_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaad.2022.12.024","volume":"90","author":"E Baumrin","year":"2024","unstructured":"Baumrin E, Loren AW, Falk SJ, Mays JW, Cowen EW. Chronic graft-versus-host disease. Part I: Epidemiology, pathogenesis, and clinical manifestations. J Am Acad Dermatol. 2024;90:1\u201316. https:\/\/doi.org\/10.1016\/j.jaad.2022.12.024.","journal-title":"J Am Acad Dermatol"},{"key":"2817_CR53","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.jtct.2022.05.038","volume":"28","author":"GDE Cuvelier","year":"2022","unstructured":"Cuvelier GDE, Schoettler M, Buxbaum NP, Pinal-Fernandez I, Schmalzing M, Distler JHW, et al. Toward a Better Understanding of the Atypical Features of Chronic Graft-Versus-Host Disease: A Report from the 2020 National Institutes of Health Consensus Project Task Force. Transpl Cell Ther. 2022;28:426\u201345. https:\/\/doi.org\/10.1016\/j.jtct.2022.05.038.","journal-title":"Transpl Cell Ther"},{"key":"2817_CR54","doi-asserted-by":"publisher","first-page":"663.e661","DOI":"10.1016\/j.jtct.2021.04.017","volume":"27","author":"J Yu","year":"2021","unstructured":"Yu J, Du Y, Ahmad S, Patel RD, Varela JC, Chang CC, et al. Comparison of Myeloablative versus Reduced-Intensity Conditioning Regimens in Allogeneic Stem Cell Transplantation Recipients with Acute Myelogenous Leukemia with Measurable Residual Disease-Negative Disease at the Time of Transplantation: A Retrospective Cohort Study. Transpl Cell Ther. 2021;27:663.e661\u2013663.e666. https:\/\/doi.org\/10.1016\/j.jtct.2021.04.017.","journal-title":"Transpl Cell Ther"},{"key":"2817_CR55","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1200\/JCO.2016.70.7091","volume":"35","author":"BL Scott","year":"2017","unstructured":"Scott BL, Pasquini MC, Logan BR, Wu J, Devine SM, Porter DL, et al. Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes. J Clin Oncol. 2017;35:1154\u201361. https:\/\/doi.org\/10.1200\/JCO.2016.70.7091.","journal-title":"J Clin Oncol"},{"key":"2817_CR56","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1200\/jco.20.01086","volume":"39","author":"B Watkins","year":"2021","unstructured":"Watkins B, Qayed M, McCracken C, Bratrude B, Betz K, Suessmuth Y, et al. Phase II Trial of Costimulation Blockade With Abatacept for Prevention of Acute GVHD. J Clin Oncol. 2021;39:1865\u201377. https:\/\/doi.org\/10.1200\/jco.20.01086.","journal-title":"J Clin Oncol"},{"key":"2817_CR57","doi-asserted-by":"publisher","first-page":"e293","DOI":"10.1016\/s2352-3026(17)30081-9","volume":"4","author":"J Finke","year":"2017","unstructured":"Finke J, Schmoor C, Bethge WA, Ottinger H, Stelljes M, Volin L, et al. Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial. Lancet Haematol. 2017;4:e293\u2013e301. https:\/\/doi.org\/10.1016\/s2352-3026(17)30081-9.","journal-title":"Lancet Haematol"},{"key":"2817_CR58","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1056\/NEJMoa1506002","volume":"374","author":"N Kr\u00f6ger","year":"2016","unstructured":"Kr\u00f6ger N, Solano C, Wolschke C, Bandini G, Patriarca F, Pini M, et al. Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease. N Engl J Med. 2016;374:43\u201353. https:\/\/doi.org\/10.1056\/NEJMoa1506002.","journal-title":"N Engl J Med"},{"key":"2817_CR59","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/s41409-025-02538-w","volume":"60","author":"AHG Stuut","year":"2025","unstructured":"Stuut AHG, Nijssen C, van der Wagen L, van Rhenen A, Daenen LGM, Janssen A, et al. Improved GVHD-free and relapse-free survival after ex vivo \u03b1\u03b2TCR and CD19 depleted allogeneic HSCT compared to T cell replete HSCT. Bone Marrow Transpl. 2025;60:673\u201381. https:\/\/doi.org\/10.1038\/s41409-025-02538-w.","journal-title":"Bone Marrow Transpl"},{"key":"2817_CR60","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1200\/jco.21.01755","volume":"40","author":"M Bleakley","year":"2022","unstructured":"Bleakley M, Sehgal A, Seropian S, Biernacki MA, Krakow EF, Dahlberg A, et al. Naive T-Cell Depletion to Prevent Chronic Graft-Versus-Host Disease. J Clin Oncol. 2022;40:1174\u201385. https:\/\/doi.org\/10.1200\/jco.21.01755.","journal-title":"J Clin Oncol"},{"key":"2817_CR61","doi-asserted-by":"publisher","unstructured":"Meyer E, Salhotra A, Gandhi A, Pantin J, Patel SS, Hoeg RT et al. Orca-T versus allogeneic hematopoietic stem cell transplantation (PRECISION-T): a multicenter, randomized phase 3 trial. Blood 2025. https:\/\/doi.org\/10.1182\/blood.2025031313.","DOI":"10.1182\/blood.2025031313"},{"key":"2817_CR62","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.1182\/blood-2010-08-302109","volume":"117","author":"ME Flowers","year":"2011","unstructured":"Flowers ME, Inamoto Y, Carpenter PA, Lee SJ, Kiem HP, Petersdorf EW, et al. Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. Blood. 2011;117:3214\u20139. https:\/\/doi.org\/10.1182\/blood-2010-08-302109.","journal-title":"Blood"},{"key":"2817_CR63","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1001\/jamaoncol.2019.3541","volume":"5","author":"N Gagelmann","year":"2019","unstructured":"Gagelmann N, Bacigalupo A, Rambaldi A, Hoelzer D, Halter J, Sanz J, et al. Haploidentical Stem Cell Transplantation With Posttransplant Cyclophosphamide Therapy vs Other Donor Transplantations in Adults With Hematologic Cancers: A Systematic Review and Meta-analysis. JAMA Oncol. 2019;5:1739\u201348. https:\/\/doi.org\/10.1001\/jamaoncol.2019.3541.","journal-title":"JAMA Oncol"},{"key":"2817_CR64","doi-asserted-by":"publisher","first-page":"S68","DOI":"10.1016\/j.bbmt.2015.11.360","volume":"22","author":"L Muffly","year":"2016","unstructured":"Muffly L, Pasquini MC, Martens M, Brazauskas R, Zhu X, Adekola K, et al. Increasing Use of Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients Age 70 Years and Older: A CIBMTR Study of Trends and Outcomes. Biol Blood Marrow Transpl. 2016;22:S68\u2013S69. https:\/\/doi.org\/10.1016\/j.bbmt.2015.11.360.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2817_CR65","doi-asserted-by":"publisher","first-page":"298","DOI":"10.3324\/haematol.2010.029702","volume":"96","author":"E Castermans","year":"2011","unstructured":"Castermans E, Hannon M, Dutrieux J, Humblet-Baron S, Seidel L, Cheynier R, et al. Thymic recovery after allogeneic hematopoietic cell transplantation with non-myeloablative conditioning is limited to patients younger than 60 years of age. Haematologica. 2011;96:298\u2013306. https:\/\/doi.org\/10.3324\/haematol.2010.029702.","journal-title":"Haematologica"},{"key":"2817_CR66","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","volume":"11","author":"AH Filipovich","year":"2005","unstructured":"Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transpl. 2005;11:945\u201356. https:\/\/doi.org\/10.1016\/j.bbmt.2005.09.004.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2817_CR67","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/0002-9343(80)90380-0","volume":"69","author":"HM Shulman","year":"1980","unstructured":"Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med. 1980;69:204\u201317. https:\/\/doi.org\/10.1016\/0002-9343(80)90380-0.","journal-title":"Am J Med"},{"key":"2817_CR68","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1053\/bbmt.2003.50026","volume":"9","author":"SJ Lee","year":"2003","unstructured":"Lee SJ, Vogelsang G, Flowers ME. Chronic graft-versus-host disease. Biol Blood Marrow Transpl. 2003;9:215\u201333. https:\/\/doi.org\/10.1053\/bbmt.2003.50026.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2817_CR69","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/bmt.2013.129","volume":"49","author":"RF Duarte","year":"2014","unstructured":"Duarte RF, Greinix H, Rabin B, Mitchell SA, Basak G, Wolff D, et al. Uptake and use of recommendations for the diagnosis, severity scoring and management of chronic GVHD: an international survey of the EBMT-NCI Chronic GVHD Task Force. Bone Marrow Transpl. 2014;49:49\u201354. https:\/\/doi.org\/10.1038\/bmt.2013.129.","journal-title":"Bone Marrow Transpl"},{"key":"2817_CR70","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.jtct.2021.03.033","volume":"27","author":"CL Kitko","year":"2021","unstructured":"Kitko CL, Pidala J, Schoemans HM, Lawitschka A, Flowers ME, Cowen EW, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIa. The 2020 Clinical Implementation and Early Diagnosis Working Group Report. Transpl Cell Ther. 2021;27:545\u201357. https:\/\/doi.org\/10.1016\/j.jtct.2021.03.033.","journal-title":"Transpl Cell Ther"},{"key":"2817_CR71","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.jtct.2025.06.030","volume":"31","author":"R Banerjee","year":"2025","unstructured":"Banerjee R, Amonoo HL, Barata A, Bhatt NS, Espinoza-Gutarra MR, Jayani-Kosarzycki RV, et al. Assessing Quality of Life and Symptoms in Transplantation and CAR-T Recipients: Expert Panel Recommendations from the Survivorship Special Interest Group of ASTCT. Transpl Cell Ther. 2025;31:774\u201388. https:\/\/doi.org\/10.1016\/j.jtct.2025.06.030.","journal-title":"Transpl Cell Ther"},{"key":"2817_CR72","doi-asserted-by":"publisher","first-page":"470.e471","DOI":"10.1016\/j.jtct.2023.04.004","volume":"29","author":"J Yu","year":"2023","unstructured":"Yu J, Khera N, Turnbull J, Stewart SK, Williams P, Bhatt V, et al. Impact of Chronic Graft-versus-Host Disease on Patient Employment, Income, and Informal Caregiver Burden: Findings From the Living With Chronic GVHD Patient Survey. Transpl Cell Ther. 2023;29:470.e471\u2013470.e479. https:\/\/doi.org\/10.1016\/j.jtct.2023.04.004.","journal-title":"Transpl Cell Ther"},{"key":"2817_CR73","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1016\/j.bbmt.2018.07.020","volume":"24","author":"A El-Jawahri","year":"2018","unstructured":"El-Jawahri A, Pidala J, Khera N, Wood WA, Arora M, Carpenter PA, et al. Impact of Psychological Distress on Quality of Life, Functional Status, and Survival in Patients with Chronic Graft-versus-Host Disease. Biol Blood Marrow Transpl. 2018;24:2285\u201392. https:\/\/doi.org\/10.1016\/j.bbmt.2018.07.020.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2817_CR74","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/bmt.2015.195","volume":"51","author":"C Fiuza-Luces","year":"2016","unstructured":"Fiuza-Luces C, Simpson RJ, Ram\u00edrez M, Lucia A, Berger NA. Physical function and quality of life in patients with chronic GvHD: a summary of preclinical and clinical studies and a call for exercise intervention trials in patients. Bone Marrow Transpl. 2016;51:13\u201326. https:\/\/doi.org\/10.1038\/bmt.2015.195.","journal-title":"Bone Marrow Transpl"},{"key":"2817_CR75","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1007\/s11764-023-01354-9","volume":"17","author":"JL Hansen","year":"2023","unstructured":"Hansen JL, Juckett MB, Foster MA, Rumble ME, Morris KE, Hematti P, et al. Psychological and physical function in allogeneic hematopoietic cell transplant survivors with chronic graft-versus-host disease. J Cancer Surviv. 2023;17:646\u201356. https:\/\/doi.org\/10.1007\/s11764-023-01354-9.","journal-title":"J Cancer Surviv"},{"key":"2817_CR76","doi-asserted-by":"publisher","first-page":"e214","DOI":"10.1016\/s2352-3026(24)00357-0","volume":"12","author":"H Schoemans","year":"2025","unstructured":"Schoemans H, Stienissen E, Goris K, Stewart SK, Cowden M, Arnahoutova K, et al. Ask, do not tell: consulting a patient advisory board to understand unmet needs of patients with GVHD in Europe. Lancet Haematol. 2025;12:e214\u2013e223. https:\/\/doi.org\/10.1016\/s2352-3026(24)00357-0.","journal-title":"Lancet Haematol"},{"key":"2817_CR77","doi-asserted-by":"publisher","first-page":"e191","DOI":"10.1016\/j.bbmt.2019.01.018","volume":"25","author":"J Mohammed","year":"2019","unstructured":"Mohammed J, Smith SR, Burns L, Basak G, Aljurf M, Savani BN, et al. Role of Physical Therapy before and after Hematopoietic Stem Cell Transplantation: White Paper Report. Biol Blood Marrow Transpl. 2019;25:e191\u2013e198. https:\/\/doi.org\/10.1016\/j.bbmt.2019.01.018.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2817_CR78","doi-asserted-by":"publisher","first-page":"e780","DOI":"10.1016\/s2352-3026(24)00209-6","volume":"11","author":"T Alsuliman","year":"2024","unstructured":"Alsuliman T, Alasadi L, Polomeni A, Capes A, Peric Z, Linke A, et al. Sexual health-related psychological and emotional life after allogeneic haematopoietic stem-cell transplantation. Lancet Haematol. 2024;11:e780\u2013e791. https:\/\/doi.org\/10.1016\/s2352-3026(24)00209-6.","journal-title":"Lancet Haematol"},{"key":"2817_CR79","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/s41409-022-01881-6","volume":"58","author":"I Moiseev","year":"2023","unstructured":"Moiseev I, Ambron P, Badoglio M, Peczynski C, Basak G, Koenecke C, et al. Steroid-free first line treatment of moderate and severe chronic GVHD: a survey from the Transplant Complications Working Party of the EBMT. Bone Marrow Transpl. 2023;58:325\u20137. https:\/\/doi.org\/10.1038\/s41409-022-01881-6.","journal-title":"Bone Marrow Transpl"},{"key":"2817_CR80","doi-asserted-by":"publisher","first-page":"678.e671","DOI":"10.1016\/j.jtct.2025.05.016","volume":"31","author":"SJ Lee","year":"2025","unstructured":"Lee SJ, Williams KM, Sarantopoulos S, Kitko CL, Cutler C, Pidala J, et al. NIH Chronic Graft-Versus-Host Disease Consensus Conference 2025 Update. Transpl Cell Ther. 2025;31:678.e671\u2013678.e616. https:\/\/doi.org\/10.1016\/j.jtct.2025.05.016.","journal-title":"Transpl Cell Ther"},{"key":"2817_CR81","doi-asserted-by":"publisher","unstructured":"Loren AW, Mielcarek M, Bola\u00f1os-Meade J, Brammer J, Cowden M, Di Stasi A et al. Hematopoietic Cell Transplantation, Version 3.2025, NCCN Clinical Practice Guidelines In Oncology. J Natl Compr Canc Netw 2025; 23. https:\/\/doi.org\/10.6004\/jnccn.2025.0047.","DOI":"10.6004\/jnccn.2025.0047"},{"key":"2817_CR82","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1182\/blood-2014-03-563544","volume":"124","author":"Y Inamoto","year":"2014","unstructured":"Inamoto Y, Flowers ME, Sandmaier BM, Aki SZ, Carpenter PA, Lee SJ, et al. Failure-free survival after initial systemic treatment of chronic graft-versus-host disease. Blood. 2014;124:1363\u201371. https:\/\/doi.org\/10.1182\/blood-2014-03-563544.","journal-title":"Blood"},{"key":"2817_CR83","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1182\/blood-2017-07-793786","volume":"130","author":"D Miklos","year":"2017","unstructured":"Miklos D, Cutler CS, Arora M, Waller EK, Jagasia M, Pusic I, et al. Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. Blood. 2017;130:2243\u201350. https:\/\/doi.org\/10.1182\/blood-2017-07-793786.","journal-title":"Blood"},{"key":"2817_CR84","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1056\/NEJMoa2033122","volume":"385","author":"R Zeiser","year":"2021","unstructured":"Zeiser R, Polverelli N, Ram R, Hashmi SK, Chakraverty R, Middeke JM, et al. Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease. N Engl J Med. 2021;385:228\u201338. https:\/\/doi.org\/10.1056\/NEJMoa2033122.","journal-title":"N Engl J Med"},{"key":"2817_CR85","doi-asserted-by":"publisher","first-page":"2566","DOI":"10.1200\/jco-24-02477","volume":"43","author":"R Zeiser","year":"2025","unstructured":"Zeiser R, Russo D, Ram R, Hashmi SK, Chakraverty R, Middeke JM, et al. Ruxolitinib in Patients With Corticosteroid-Refractory or Corticosteroid-Dependent Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of the Phase III REACH3 Study. J Clin Oncol. 2025;43:2566\u201371. https:\/\/doi.org\/10.1200\/jco-24-02477.","journal-title":"J Clin Oncol"},{"key":"2817_CR86","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1182\/blood.2021012021","volume":"138","author":"C Cutler","year":"2021","unstructured":"Cutler C, Lee SJ, Arai S, Rotta M, Zoghi B, Lazaryan A, et al. Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study. Blood. 2021;138:2278\u201389. https:\/\/doi.org\/10.1182\/blood.2021012021.","journal-title":"Blood"},{"key":"2817_CR87","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1200\/jco.20.02754","volume":"39","author":"M Jagasia","year":"2021","unstructured":"Jagasia M, Lazaryan A, Bachier CR, Salhotra A, Weisdorf DJ, Zoghi B, et al. ROCK2 Inhibition With Belumosudil (KD025) for the Treatment of Chronic Graft-Versus-Host Disease. J Clin Oncol. 2021;39:1888\u201398. https:\/\/doi.org\/10.1200\/jco.20.02754.","journal-title":"J Clin Oncol"},{"key":"2817_CR88","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/NEJMoa2401537","volume":"391","author":"D Wolff","year":"2024","unstructured":"Wolff D, Cutler C, Lee SJ, Pusic I, Bittencourt H, White J, et al. Axatilimab in Recurrent or Refractory Chronic Graft-versus-Host Disease. N Engl J Med. 2024;391:1002\u201314. https:\/\/doi.org\/10.1056\/NEJMoa2401537.","journal-title":"N Engl J Med"},{"key":"2817_CR89","doi-asserted-by":"publisher","first-page":"S534","DOI":"10.1016\/j.jtct.2024.05.019","volume":"30","author":"DJ Epstein","year":"2024","unstructured":"Epstein DJ, Otoukesh S, Shahid Z, Dadwal SS. Infectious Disease Considerations in Chronic Graft-versus-Host Disease and Transplantation Survivors. Transpl Cell Ther. 2024;30:S534\u2013S547. https:\/\/doi.org\/10.1016\/j.jtct.2024.05.019.","journal-title":"Transpl Cell Ther"},{"key":"2817_CR90","doi-asserted-by":"publisher","unstructured":"Battipaglia G, Wehr C, Admiraal R, Nierkens S, Malard F, Zeiser R et al. Usage of rabbit anti-thymocyte \/ anti-T-lymphocyte globulins (ATG \/ ATLG) for hematological malignancies in allogeneic hematopoietic cell transplantation: Best practice recommendations from the EBMT Practice Harmonisation and Guidelines Committee. Bone Marrow Transpl. 2025. https:\/\/doi.org\/10.1038\/s41409-025-02742-8.","DOI":"10.1038\/s41409-025-02742-8"},{"key":"2817_CR91","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1002\/ajh.27040","volume":"98","author":"F Malard","year":"2023","unstructured":"Malard F, Mohty M. Updates in chronic graft-versus-host disease management. Am J Hematol. 2023;98:1637\u201344. https:\/\/doi.org\/10.1002\/ajh.27040.","journal-title":"Am J Hematol"},{"key":"2817_CR92","doi-asserted-by":"publisher","first-page":"4886","DOI":"10.1182\/bloodadvances.2022007611","volume":"7","author":"NP Buxbaum","year":"2023","unstructured":"Buxbaum NP, Soci\u00e9 G, Hill GR, MacDonald KPA, Tkachev V, Teshima T, et al. Chronic GvHD NIH Consensus Project Biology Task Force: evolving path to personalized treatment of chronic GvHD. Blood Adv. 2023;7:4886\u2013902. https:\/\/doi.org\/10.1182\/bloodadvances.2022007611.","journal-title":"Blood Adv"},{"key":"2817_CR93","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1182\/blood.2025028617","volume":"146","author":"G Socie","year":"2025","unstructured":"Socie G. Challenges in GVHD and GVL after hematopoietic stem cell transplantation for myeloid malignancies. Blood. 2025;146:926\u201337. https:\/\/doi.org\/10.1182\/blood.2025028617.","journal-title":"Blood"},{"key":"2817_CR94","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.3324\/haematol.2025.287390","volume":"110","author":"HT Kim","year":"2025","unstructured":"Kim HT, Soiffer RJ, Cutler C, Koreth J, Nikiforow S, Shapiro RM, et al. Reduced incidence of relapse and graft-versus-host disease in acute myeloid leukemia after allogeneic hematopoietic cell transplantation. Haematologica. 2025;110:1998\u20132008. https:\/\/doi.org\/10.3324\/haematol.2025.287390.","journal-title":"Haematologica"},{"key":"2817_CR95","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.jtct.2021.02.035","volume":"27","author":"KM Williams","year":"2021","unstructured":"Williams KM, Inamoto Y, Im A, Hamilton B, Koreth J, Arora M, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2020 Etiology and Prevention Working Group Report. Transpl Cell Ther. 2021;27:452\u201366. https:\/\/doi.org\/10.1016\/j.jtct.2021.02.035.","journal-title":"Transpl Cell Ther"},{"key":"2817_CR96","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/j.jtct.2021.06.001","volume":"27","author":"D Wolff","year":"2021","unstructured":"Wolff D, Radojcic V, Lafyatis R, Cinar R, Rosenstein RK, Cowen EW, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2020 Highly morbid forms report. Transpl Cell Ther. 2021;27:817\u201335. https:\/\/doi.org\/10.1016\/j.jtct.2021.06.001.","journal-title":"Transpl Cell Ther"},{"key":"2817_CR97","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.jtct.2021.03.029","volume":"27","author":"J Pidala","year":"2021","unstructured":"Pidala J, Kitko C, Lee SJ, Carpenter P, Cuvelier GDE, Holtan S, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIb. The 2020 Preemptive Therapy Working Group Report. Transpl Cell Ther. 2021;27:632\u201341. https:\/\/doi.org\/10.1016\/j.jtct.2021.03.029.","journal-title":"Transpl Cell Ther"},{"key":"2817_CR98","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1016\/j.ymthe.2022.02.025","volume":"30","author":"S Landwehr-Kenzel","year":"2022","unstructured":"Landwehr-Kenzel S, M\u00fcller-Jensen L, Kuehl J-S, Abou-el-Enein M, Hoffmann H, Muench S, et al. Adoptive transfer of ex vivo expanded regulatory T cells improves immune cell engraftment and therapy-refractory chronic GvHD. Mol Ther. 2022;30:2298\u2013314. https:\/\/doi.org\/10.1016\/j.ymthe.2022.02.025.","journal-title":"Mol Ther"},{"key":"2817_CR99","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1002\/sctm.20-0099","volume":"9","author":"E Boberg","year":"2020","unstructured":"Boberg E, von, Bahr L, Afram G, Lindstr\u00f6m C, Ljungman P, et al. Treatment of chronic GvHD with mesenchymal stromal cells induces durable responses: A phase II study. STEM CELLS Transl Med. 2020;9:1190\u2013202. https:\/\/doi.org\/10.1002\/sctm.20-0099.","journal-title":"STEM CELLS Transl Med"},{"key":"2817_CR100","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s10198-020-01249-x","volume":"22","author":"F Schain","year":"2021","unstructured":"Schain F, Batyrbekova N, Liwing J, Baculea S, Webb T, Remberger M, et al. Real-world study of direct medical and indirect costs and time spent in healthcare in patients with chronic graft versus host disease. Eur J Health Econ. 2021;22:169\u201380. https:\/\/doi.org\/10.1007\/s10198-020-01249-x.","journal-title":"Eur J Health Econ"},{"key":"2817_CR101","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/j.bbmt.2015.02.025","volume":"21","author":"SJ Lee","year":"2015","unstructured":"Lee SJ, Wolff D, Kitko C, Koreth J, Inamoto Y, Jagasia M, et al. Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group report. Biol Blood Marrow Transpl. 2015;21:984\u201399. https:\/\/doi.org\/10.1016\/j.bbmt.2015.02.025.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2817_CR102","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1038\/s41409-018-0092-x","volume":"53","author":"D Wolff","year":"2018","unstructured":"Wolff D, Greinix H, Lee SJ, Gooley T, Paczesny S, Pavletic S, et al. Biomarkers in chronic graft-versus-host disease: quo vadis?. Bone Marrow Transpl. 2018;53:832\u20137. https:\/\/doi.org\/10.1038\/s41409-018-0092-x.","journal-title":"Bone Marrow Transpl"},{"key":"2817_CR103","doi-asserted-by":"publisher","first-page":"4548","DOI":"10.1182\/blood-2005-03-1262","volume":"105","author":"AD Hess","year":"2005","unstructured":"Hess AD. Chronic graft-versus-host disease: a breakdown of self-tolerance?. Blood. 2005;105:4548\u20139. https:\/\/doi.org\/10.1182\/blood-2005-03-1262.","journal-title":"Blood"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02817-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02817-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02817-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T14:19:15Z","timestamp":1775571555000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02817-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,7]]},"references-count":103,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["2817"],"URL":"https:\/\/doi.org\/10.1038\/s41409-026-02817-0","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,7]]},"assertion":[{"value":"24 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"FM reports lecture honoraria from Sanofi, Novartis, BMS, Astrazeneca, Therakos, Priothera, MSD and Jazz Pharmaceutical all outside the submitted work. MV reports speaker honoraria from Novartis, Celgene, Gilead, Pfizer, Incyte, Jazz Pharma, Sanofi and Mundipharma, Therakos, advisory board honoraria from Gilead, Pfizer, Sanofi, Mundipharma and Therakos and research grants from Gilead, MSD, Pfizer and MRC. MM reports grants and lecture honoraria from Janssen, Sanofi, Maat Pharma and JAZZ Pharmaceuticals, lecture honoraria from Celgene, Amgen, BMS, Takeda, and Pfizer, grants from Roche, all outside the submitted work. The other authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}